AxoGen, Inc (NASDAQ:AXGN) SVP Shawn F. Mccarrey sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, May 16th. The shares were sold at an average price of $43.47, for a total value of $434,700.00. Following the transaction, the senior vice president now owns 33,057 shares of the company’s stock, valued at $1,436,987.79. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
AXGN stock opened at $43.95 on Monday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.32 and a quick ratio of 2.81. AxoGen, Inc has a 1 year low of $13.95 and a 1 year high of $46.00.
AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Monday, April 30th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). The company had revenue of $17.30 million for the quarter, compared to analyst estimates of $17.16 million. AxoGen had a negative return on equity of 61.66% and a negative net margin of 18.83%. The company’s quarterly revenue was up 41.8% compared to the same quarter last year. analysts anticipate that AxoGen, Inc will post -0.38 earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of AXGN. William Blair Investment Management LLC acquired a new stake in shares of AxoGen during the 4th quarter worth about $5,081,000. BlackRock Inc. raised its position in shares of AxoGen by 29.7% during the 4th quarter. BlackRock Inc. now owns 1,785,891 shares of the medical equipment provider’s stock worth $50,540,000 after acquiring an additional 408,596 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of AxoGen by 63.5% during the 4th quarter. Renaissance Technologies LLC now owns 657,800 shares of the medical equipment provider’s stock worth $18,616,000 after acquiring an additional 255,400 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of AxoGen during the 4th quarter worth about $662,000. Finally, Proficio Capital Partners LLC raised its position in shares of AxoGen by 5.6% during the 4th quarter. Proficio Capital Partners LLC now owns 67,600 shares of the medical equipment provider’s stock worth $1,913,000 after acquiring an additional 3,600 shares in the last quarter. 71.02% of the stock is currently owned by institutional investors.
A number of brokerages recently commented on AXGN. ValuEngine upgraded AxoGen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target (up previously from $37.00) on shares of AxoGen in a research report on Tuesday, May 1st. JMP Securities increased their price target on AxoGen from $34.00 to $43.00 and gave the company a “market outperform” rating in a research report on Tuesday, May 1st. Lake Street Capital set a $38.00 price target on AxoGen and gave the company a “buy” rating in a research report on Friday, March 2nd. Finally, William Blair began coverage on AxoGen in a research report on Monday, February 5th. They issued an “outperform” rating on the stock. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $35.57.
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.